Cochrane · systematic review · CD002063
Intravenous immunoglobulin for Guillain‐Barré syndrome
Hughes, RAC, Swan, AV, van Doorn, PA · Cochrane Database of Systematic Reviews · 2014 · Cochrane Library
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
6
current version
GRADE rated
6
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 0 · 0%Very low 0 · 0%Low 2 · 33.3%Moderate 3 · 50%High 1 · 16.7%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Current version onlyIVIg versus PE for Guillain‐Barré syndrome
Population: patients with Guillain‐Barré syndrome
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Change in disability grade 4 weeks after randomisation IVIg vs PE | no estimate extracted | 5 studies · 536 participants | Moderate Downgraded: risk of bias |
Number improved by 1 or more disability grades after 4 weeks IVIg vs PE | RR 1.08 [0.94, 1.23] | 6 studies · 567 participants | Moderate Downgraded: risk of bias |
Dead or disabled after 12 months (48 weeks) IVIg vs PE | RR 0.98 [0.55, 1.72] | 1 study · 243 participants | Low Downgraded: risk of bias |
Relapse or treatment‐related fluctuation IVIg vs PE | RR 0.89 [0.42, 1.89] | 3 studies · 445 participants | Low Downgraded: risk of bias |
Participants in whom treatment was discontinued IVIg vs PE | RR 0.14 [0.05, 0.36] | 4 studies · 498 participants | High |
Number of participants with adverse events attributed to treatment IVIg vs PE | RR 0.84 [0.54, 1.3] | 4 studies · 388 participants | Moderate Downgraded: risk of bias |
IVIg versus PE for Guillain‐Barré syndrome
Population: patients with Guillain‐Barré syndrome
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Change in disability grade 4 weeks after randomisation IVIg vs PE | no estimate extracted | 5 studies · 536 participants | Moderate Downgraded: risk of bias |
Number improved by 1 or more disability grades after 4 weeks IVIg vs PE | RR 1.08 [0.94, 1.23] | 6 studies · 567 participants | Moderate Downgraded: risk of bias |
Dead or disabled after 12 months (48 weeks) IVIg vs PE | RR 0.98 [0.55, 1.72] | 1 study · 243 participants | Low Downgraded: risk of bias |
Relapse or treatment‐related fluctuation IVIg vs PE | RR 0.89 [0.42, 1.89] | 3 studies · 445 participants | Low Downgraded: risk of bias |
Patients in whom treatment was discontinued IVIg vs PE | RR 0.14 [0.05, 0.36] | 4 studies · 498 participants | High |
Number of patients with adverse events attributed to treatment IVIg vs PE | RR 0.84 [0.54, 1.3] | 4 studies · 388 participants | Moderate Downgraded: risk of bias |
IVIg compared to PE (control) for Guillain‐Barré syndrome
Population: patients with Guillain‐Barré syndrome
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Change in disability grade 4 weeks after randomisation disability grade change. Scale from: +4 to ‐5. IVIg vs PE (control) | no estimate extracted | 5 studies · 536 participants | Moderate Downgraded: risk of bias |
Dead or disabled after 12 months (48 weeks) IVIg vs PE (control) | RR 0.98 [0.55, 1.72] | 1 study · 243 participants | Low Downgraded: risk of bias |
Relapse or treatment‐related fluctuation IVIg vs PE (control) | RR 0.89 [0.42, 1.89] | 3 studies · 445 participants | Low Downgraded: risk of bias |
Number of patients with adverse events attributed to treatment IVIg vs PE (control) | RR 0.84 [0.54, 1.3] | 3 studies · 347 participants | Moderate Downgraded: risk of bias |
Patients in whom treatment was discontinued IVIg vs PE (control) | RR 0.14 [0.05, 0.36] | 4 studies · 495 participants | Moderate Downgraded: risk of bias |
Number improved by 1 or more disability grades after 4 weeks IVIg vs PE (control) | RR 1.09 [0.94, 1.27] | 5 studies · 526 participants | Moderate Downgraded: risk of bias |